# Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

> **NCT00409175** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 128 (actual)

## Conditions studied

- Familial Amyloid Polyneuropathy

## Interventions

- **DRUG:** Fx-1006A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00409175
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2012-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409175, "Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00409175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*